Optimal level of hemoglobin in cancer patients


In human beings, the hemoglobin level is dependent on sex and age. Women usually have a lower hemoglobin level than men, and there is evidence of a decrease in hemoglobin level with increasing age (Nilsson-Ehle et al. 2000; Rushton et al. 2001). In men hemoglobin level normally ranges between 13.3–17.7 g/dl and in women between 11.7–15.7 g/dl (Williams 1988; Fairbanks and Tefferi 2000). According to the World Health Organization, anemia is defined as hemoglobin level <13 g/dl in men and <12 g/dl in women (World Health Organization 1968). Clinical and epidemiological studies show that anemia is generally associated with increased mortality, even in elderly persons in the general population (Izaks et al. 1999; Collins et al. 2000; Caro et al. 2001).


Hemoglobin Level Recombinant Human Erythropoietin Nephrol Dial Transplant Globin Level Target Hemoglobin Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nutritional Anemias (1968) Report of a WHO scientific group. World Health Organization: GenevaGoogle Scholar
  2. 2.
    Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A (Suppl 2): S2 - S8CrossRefGoogle Scholar
  3. 3.
    Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N (2001) Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 37 (Suppl 6): S144 (abstract)CrossRefGoogle Scholar
  4. 4.
    Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P (2000) Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18: 4–11PubMedGoogle Scholar
  5. 5.
    Barany P, Pettersson E, Ahlberg M, Hultman E, Bergstrom J (1991) Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 35: 270–279PubMedGoogle Scholar
  6. 6.
    Becker A, Stadler P, Lavey RS, Hänsgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M, Dunst J (2000) Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 46: 459–466PubMedCrossRefGoogle Scholar
  7. 7.
    Benz RL, Pressman MR, Hovick ET, Peterson DD (1999) A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients ( The SLEEPO study ). Am J Kidney Dis 34: 1089–1095PubMedCrossRefGoogle Scholar
  8. 8.
    Berry WR, Laszlo J, Cox E, Walker A, Paulson D (1979) Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763–775PubMedCrossRefGoogle Scholar
  9. 9.
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590PubMedCrossRefGoogle Scholar
  10. 10.
    Besarab A, Aslam M (2001) Should the hematocrit (hemoglobin) be normalized in pre-ESRD or dialysis patients? Yes! Blood Purif 19: 168–174PubMedCrossRefGoogle Scholar
  11. 11.
    Binet JL, Lepoprier M, Dighiero G. Charron D, D’Athis P, Vaugier G, Beral HM, Natali JC, Raphael M, Nizet B, Follezou JY (1977) A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 40: 855–864.Google Scholar
  12. 12.
    Bolton WK (1999) What crit? Am J Kidney Dis 33: 1177–1179CrossRefGoogle Scholar
  13. 13.
    Brizel DM, Dodge RK, Clough RW, Dewhirst MW (1999) Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53: 113–117PubMedCrossRefGoogle Scholar
  14. 14.
    Bush RS (1986) The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12: 2047–2050PubMedCrossRefGoogle Scholar
  15. 15.
    Cabanillas F, Burke JS, Smith TL, Moon TE, Butler JJ, Rodriguez V (1978) Factors predicting for response and survival in adults with advanced non-Hodgkin’s lymphoma. Arch Intern Med 138: 413–418PubMedCrossRefGoogle Scholar
  16. 16.
    Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214–2221PubMedCrossRefGoogle Scholar
  17. 17.
    Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA, Abels RI (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801–806PubMedCrossRefGoogle Scholar
  18. 18.
    Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (Suppl 2): 13–19PubMedGoogle Scholar
  19. 19.
    Citterio G, Bertuzzi A, Tresoldi M, Galli L, Di Lucca G, Scaglietti U, Rugarli C (1997) Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 31: 286–291PubMedGoogle Scholar
  20. 20.
    Cleeland CS, Demetri GD, Glaspy J, Cella DF, Portonoy RK, Cremieux PY, Itri L (1999) Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 18: 574a (abstract)Google Scholar
  21. 21.
    Clyne N, Jogestrand T (1992) Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60: 390–396PubMedCrossRefGoogle Scholar
  22. 22.
    Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N (1989) LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7: 1018–1026PubMedGoogle Scholar
  23. 23.
    Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P (2001) Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37: 1617–1623PubMedCrossRefGoogle Scholar
  24. 24.
    Collins AJ, Ma JZ, Ebben J (2000) Impact of hematocrit on morbidity and mortality. Semin Nephrol 20: 345–349PubMedGoogle Scholar
  25. 25.
    Conlan MG, Armitage JO, Bast M, Weisenburger DD (1991) Clinical significance of hematologic parameters in non-Hodgkin’s lymphoma at diagnosis. Cancer 67: 1389–1395PubMedCrossRefGoogle Scholar
  26. 26.
    Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF (1997) Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 39: 651–657PubMedCrossRefGoogle Scholar
  27. 27.
    Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, Deakin DP, Crowther D (1989) Prognostic factors in high and intermediate grade non-Hodgkin’s lymphoma. Br J Cancer 59: 276–282PubMedCrossRefGoogle Scholar
  28. 28.
    Curt GA (2000a) The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist 5: 9–12CrossRefGoogle Scholar
  29. 29.
    Curt GA (2000b) Impact of fatigue on quality of life in oncology patients. Semin Hematol 37 (Suppl 6): 14–17PubMedCrossRefGoogle Scholar
  30. 30.
    Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000c) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5: 353–360PubMedCrossRefGoogle Scholar
  31. 31.
    Curt GA (2001) Fatigue in cancer. BMJ 322: 1560PubMedCrossRefGoogle Scholar
  32. 32.
    Daneryd P, Svanberg E, Körner U, Lindholm E, Sandström R, Brevinge H, Pettersson C, Bosaeus I, Lundholm K (1998) Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 58: 5374–5379PubMedGoogle Scholar
  33. 33.
    Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412–3425Google Scholar
  34. 34.
    Diesel W, Noakes TD, Swanepoel C, Lambert M (1990) Isokinetic muscle strength predicts maximum exercise tolerance in renal patients on chronic hemodialysis. Am J Kidney Dis 16: 109–114PubMedGoogle Scholar
  35. 35.
    Dietz A, Rudat V, Conradt C, Vanselow B, Wollensack P, Staar S, Eckel H, Volling P, Schröder M, Wannenmacher M, Muller RP, Weidauer H (2000) [Prognostic value of hemoglobin level for primary radiochemotherapy of head-neck carcinomas]. HNO 48: 655–664Google Scholar
  36. 36.
    Dische S (1991) Radiotherapy and anaemia — the clinical experience. Radiother Oncol 20 (Suppl 1): 35–40PubMedCrossRefGoogle Scholar
  37. 37.
    Drueke TB, Eckardt KU, Frei U, Jacobs C, Kokot F, McMahon LP, Schaefer RM (1999) Does early anemia correction prevent complications of chronic renal failure? Clin Nephrol 51: 1–11PubMedGoogle Scholar
  38. 38.
    Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P, Cosset JM (1996) Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201: 553–558PubMedGoogle Scholar
  39. 39.
    Dunphy EP, Petersen IA, Cox RS, Bagshaw MA (1989) The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 16: 1173–1178PubMedCrossRefGoogle Scholar
  40. 40.
    Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842–854PubMedCrossRefGoogle Scholar
  41. 41.
    Eckardt KU (2001) Target hemoglobin in patients with renal failure. Nephron 89: 135–144PubMedCrossRefGoogle Scholar
  42. 42.
    Emrich LJ, Priore RL, Murphy GP, Brady MF (1985) Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45: 5173–5179PubMedGoogle Scholar
  43. 43.
    Erslev AJ, Caro J, Schuster SJ (1989) Is there an optimal hemoglobin level? Transfus Med Rev 3: 237–242PubMedCrossRefGoogle Scholar
  44. 44.
    Eschbach JW, Glenny R, Robertson T, Guthrie M, Rader B, Evans R, Chandler W, Davidson R, Eaterling T, Denney J, Schneider G (1993) Normalizing the hematocrit in hemodialysis patients with EPO improves quality of life and is safe. J Am Soc Nephrol 4: 445 (abstract)Google Scholar
  45. 45.
    Estrin JT, Schocket L, Kregenow R, Henry DH (1999) A retrospective review of blood transfusion in cancer patients with anemia. Oncologist 4: 318–324PubMedGoogle Scholar
  46. 46.
    Evans SM, Jenkins WT, Shapiro M, Koch CJ (1997) Evaluation of the concept of “hypoxic fraction” as a descriptor of tumor oxygenation status. Adv Exp Med Biol 411: 215–225PubMedCrossRefGoogle Scholar
  47. 47.
    Fagher B, Thysell H, Monti M (1994) Effect of erythropoietin on muscle metabolic rate, as measured by direct microcalorimetry, and ATP in hemodialysis patients. Nephron 67: 167–171PubMedCrossRefGoogle Scholar
  48. 48.
    Fairbanks VF, Tefferi A (2000) Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to “apparent polycythemia”. Eur J Haematol 65: 285–296PubMedCrossRefGoogle Scholar
  49. 49.
    Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR (1995) Pretreatment hemoglobin level influences local control and survival of T1–T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13: 2077–2083PubMedGoogle Scholar
  50. 50.
    Ferme C, Bastion Y, Brice P, Lederlin P, Divine M, Gabarre J, Assouline D, Ferrant A, Berger F, Lepage E (1997) Prognosis of patients with advanced Hodgkin’s disease: evaluation of four prognostic models using 344 patients included in the Groupe d’Etudes des Lymphomes de l’Adulte Study. Cancer 80: 1124–1133PubMedCrossRefGoogle Scholar
  51. 51.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1996) The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53–61PubMedCrossRefGoogle Scholar
  52. 52.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1998) Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 54: 1720–1725PubMedCrossRefGoogle Scholar
  53. 53.
    Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE (2000a) Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11: 912–916PubMedGoogle Scholar
  54. 54.
    Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA (2000b) Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325–1335PubMedCrossRefGoogle Scholar
  55. 55.
    Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48: 149–156PubMedCrossRefGoogle Scholar
  56. 56.
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875–2882PubMedGoogle Scholar
  57. 57.
    Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA (1986) Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4: 1470–1480PubMedGoogle Scholar
  58. 58.
    Gelb AB (1997) Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 981–986PubMedCrossRefGoogle Scholar
  59. 59.
    Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, Malaise EP, Haie C, Gerbaulet A, Chassagne D (1989) Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16: 37–42PubMedCrossRefGoogle Scholar
  60. 60.
    Glaser C, Millesi W, Wanschitz F, Schüll B, Lang S, Leitha T, Kornek GV (1999) R-HuErythropoietin treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patients with oral squamous cell carcinoma: a 17 month follow up. Proc Am Soc Clin Oncol 18: 399a (abstract)Google Scholar
  61. 61.
    Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705–715PubMedCrossRefGoogle Scholar
  62. 62.
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218–1234PubMedGoogle Scholar
  63. 63.
    Glaus A, Müller S (2000) [Hemoglobin and fatigue in cancer patients: inseparable twins?]. Schweiz Med Wochenschr 130: 471–477Google Scholar
  64. 64.
    Glimelius B, Linné T, Hoffman K, Larsson L, Svensson JH, Näsman P, Svensson B, Helmers C (1998) Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16: 434–440PubMedGoogle Scholar
  65. 65.
    Gobbi PG, Zinzani PL, Broglia C, Comelli M, Magagnoli M, Federico M, Merli F, Iannitto E, Tura S, Ascari E (2001) Comparison of prognostic models in patients with advanced Hodgkin disease. Cancer 91: 1467–1478PubMedCrossRefGoogle Scholar
  66. 66.
    Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, Herman JG, Garrett PG, Chua T, Duncan W et al (1989) Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 142: 1448–1453, discussion 1453–1454Google Scholar
  67. 67.
    Grau C, Overgaard J (1998) Significance of hemoglobin concentration for treatment outcome. In: Molls M, Vaupel P (eds) Blood perfusion and microenviroment of human tumors. Springer, Berlin Heidelberg New York, pp 101–102CrossRefGoogle Scholar
  68. 68.
    Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J, Schneider B (1990) Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 38: 480–486PubMedCrossRefGoogle Scholar
  69. 69.
    Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528–1536PubMedCrossRefGoogle Scholar
  70. 70.
    Harnett JD, Kent GM, Foley RN, Parfrey PS (1995) Cardiac function and hematocrit level. Am J Kidney Dis 25 (Suppl): S3 - S7PubMedCrossRefGoogle Scholar
  71. 71.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339: 1506–1514Google Scholar
  72. 72.
    Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M (2000) Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35: 250–256PubMedCrossRefGoogle Scholar
  73. 73.
    Henry DH, Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21 (Suppl 3): 21–28PubMedGoogle Scholar
  74. 74.
    Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P (1993a) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45–50PubMedCrossRefGoogle Scholar
  75. 75.
    Höckel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG (1993b) Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 51: 141–149PubMedCrossRefGoogle Scholar
  76. 76.
    Höckel M, Vaupel P (2001a) Biological consequences of tumor hypoxia. Semin Oncol 28 (Suppl 8): 36–41PubMedCrossRefGoogle Scholar
  77. 77.
    Höckel M, Vaupel P (2001b) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266–276PubMedCrossRefGoogle Scholar
  78. 78.
    Izaks GJ, Westendorp RG, Knook DL (1999) The definition of anemia in older persons. JAMA 281: 1714–1717PubMedCrossRefGoogle Scholar
  79. 79.
    Jazieh AR, Hussain M, Howington JA, Spencer HJ, Husain M, Grismer JT, Read RC (2000) Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 70: 1168–1171PubMedCrossRefGoogle Scholar
  80. 80.
    Kapp DS, Fischer D, Gutierrez E, Kohorn EI, Schwartz PE (1983) Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys 9: 445–455PubMedCrossRefGoogle Scholar
  81. 81.
    Kausz AT, Obrador GT, Pereira BJ (2000) Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 36 (Suppl): S39 - S51PubMedCrossRefGoogle Scholar
  82. 82.
    Kettner-Melsheimer A, Weiss M, Huber W (1987) Physical work capacity in chronic renal disease. Int J Artif Organs 10: 23–30PubMedGoogle Scholar
  83. 83.
    Kokot F, Wiecek A, Mesjasz J, Adamczak M, Spiechowicz U (1998) Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol Dial Transplant 13: 1200–1205PubMedCrossRefGoogle Scholar
  84. 84.
    Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, Coia LR, Rotman M, Ortiz H (1998) Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85–27. Int J Radiat Oncol Biol Phys 42: 1069–1075PubMedCrossRefGoogle Scholar
  85. 85.
    Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535–2542PubMedCrossRefGoogle Scholar
  86. 86.
    Leonard RC, Hayward RL, Prescott RJ, Wang JX (1991) The identification of discrete prognostic groups in low grade non-Hodgkin’s lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann On col 2: 655–662Google Scholar
  87. 87.
    Levin A, Foley RN (2000) Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36: S24 - S30PubMedCrossRefGoogle Scholar
  88. 88.
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874PubMedGoogle Scholar
  89. 89.
    Macdougall IC (2001) Should the hematocrit be normalized in dialysis and in pre-ESRD patients? Blood Purif 19: 157–167PubMedCrossRefGoogle Scholar
  90. 90.
    Mak RH (1996a) Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol 270: F839 - F844PubMedGoogle Scholar
  91. 91.
    Mak RH (1996b) Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr 129: 97–104PubMedCrossRefGoogle Scholar
  92. 92.
    Mak RH (1998) Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol 12: 660–665PubMedCrossRefGoogle Scholar
  93. 93.
    Mann JF (1999) What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 14: 29–36PubMedCrossRefGoogle Scholar
  94. 94.
    McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D (1999) Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 14: 1182–1187PubMedCrossRefGoogle Scholar
  95. 95.
    Metry G, Wikstrom B, Valind S, Sandhagen B, Linde T, Beshara S, Langstrom B, Danielson BG (1999) Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 10: 854–863PubMedGoogle Scholar
  96. 96.
    Mitchell TR, Pegrum GD (1971) The oxygen affinity of haemoglobin in chronic renal failure. Br J Haematol 21: 463–472PubMedCrossRefGoogle Scholar
  97. 97.
    Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B (1998) Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 9: 1109–1115PubMedCrossRefGoogle Scholar
  98. 98.
    Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, Duguid J, Knowles SM, Poole G, Williamson LM (2001) Guidelines for the clinical use of red cell transfusions. Br J Haematol 113: 24–31PubMedCrossRefGoogle Scholar
  99. 99.
    Nilsson-Ehle H, Jagenburg R, Landahl S, Svanborg A (2000) Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 65: 297–305PubMedCrossRefGoogle Scholar
  100. 100.
    Nishizawa Y, Shoji T, Tanaka S, Yamashita M, Morita A, Emoto M, Tabata T, Inoue T, Morii H (1998) Plasma leptin level and its relationship with body composition in hemodialysis patients. Am J Kidney Dis 31: 655–661PubMedCrossRefGoogle Scholar
  101. 101.
    Obermair A, Handisurya A, Kaider A, Sevelda P, Kolbl H, Gitsch G (1998) The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer 83: 726–731PubMedCrossRefGoogle Scholar
  102. 102.
    Obermair A, Cheuk R, Horwood K, Janda M, Bachtiary B, Schwanzelberger B, Stoiber A, Nicklin JL, Perrin LC, Crandon AJ (2001) Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 92: 903–908PubMedCrossRefGoogle Scholar
  103. 103.
    Oettle H, Riess H, Raguse JD, Bier J, Gath HF (2001) Recombinant human erythropoietin in the treatment of head and neck tumor anaemia. Int J Oral Maxillofac Surg 30: 148–155PubMedCrossRefGoogle Scholar
  104. 104.
    Oivanen TM (1996) Plateau phase in multiple myeloma: an analysis of longterm follow-up of 432 patients. Finnish Leukaemia Group. Br J Haematol 92: 834–839PubMedCrossRefGoogle Scholar
  105. 105.
    O’Riordan E, Foley RN (2000) Effects of anaemia on cardiovascular status. Nephrol Dial Transplant 15: 19–22PubMedGoogle Scholar
  106. 106.
    Pawlicki M, Jassem J, Bosze P, Lotan C, Kurteva GP, Siddiqui M, Kosmidis PA, Rigatos GA, Kansu E, Durkovic P, Aziz Z, Al Idrissi H, Roth A, Cozma G (1997) A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs 8: 949–957PubMedCrossRefGoogle Scholar
  107. 107.
    Pedersen D, Sogaard H, Overgaard J, Bentzen SM (1995) Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol 34: 787–795PubMedCrossRefGoogle Scholar
  108. 108.
    Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR (1999) Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33: 1122–1130PubMedCrossRefGoogle Scholar
  109. 109.
    Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC (1994) Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer 74: 2819–2827PubMedCrossRefGoogle Scholar
  110. 110.
    Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F, the Canadian Eprex Oncology Study Group (2001) Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19: 4126–4134Google Scholar
  111. 111.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234PubMedGoogle Scholar
  112. 112.
    Riedel E, Nundel M, Wendel G, Hampl H (2000) Amino acid and alpha-keto acid metabolism depends on oxygen availability in chronic hemodialysis patients. Clin Nephrol 53 (Suppl): S56 - S60Google Scholar
  113. 113.
    Ritz E, Schwenger V (2000) The optimal target hemoglobin. Semin Nephrol 20: 382–386PubMedGoogle Scholar
  114. 114.
    Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia ( MDS ). Br J Haematol 89: 831–837Google Scholar
  115. 115.
    Rossi EC (1994) Red cell transfusion therapy in chronic anemia. Hematol Oncol Clin North Am 8: 1045–1052PubMedGoogle Scholar
  116. 116.
    Rushton DH, Dover R, Sainsbury AW, Norris MJ, Gilkes JJ, Ramsay ID (2001) Why should women have lower reference limits for haemoglobin and ferritin concentrations than men? BMJ 322: 1355–1357PubMedCrossRefGoogle Scholar
  117. 117.
    Sagales T, Gimeno V, Planella MJ, Raguer N, Bartolome J (1993) Effects of rHuEPO on Q-EEG and event-related potentials in chronic renal failure. Kidney Int 44: 1109–1115PubMedCrossRefGoogle Scholar
  118. 118.
    Schreiner P, Siracka E, Siracky J, Manka I (1975) The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma 22: 655–660PubMedGoogle Scholar
  119. 119.
    Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35: 1737–1744PubMedCrossRefGoogle Scholar
  120. 120.
    Silverberg DS, Iaina A, Wexler D, Blum M (2001a) The pathological consequences of anaemia. Clin Lab Haematol 23: 1–6PubMedCrossRefGoogle Scholar
  121. 121.
    Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A (2001b) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37: 1775–1780PubMedCrossRefGoogle Scholar
  122. 122.
    Skladowski K, Tarnawski R, Maciejewski B, Wygoda A, Slosarek K (1999) Clinical radiobiology of glottic Ti squamous cell carcinoma. Int J Radiat Oncol Biol Phys 43: 101–106PubMedCrossRefGoogle Scholar
  123. 123.
    Sommerburg O, Grune T, Hampl H, Riedel E, Ehrich JH, Siems WG (2000) Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients? Clin Nephrol 53 (Suppl 1): S23 - S29PubMedGoogle Scholar
  124. 124.
    Spaia S, Pangalos M, Askepidis N, Pazarlogolou M, Mavropoulou E, Theodoridis S, Dimitrakopolous K, Milionis A, Vayonas G (2000) Nephron 84: 320–325PubMedCrossRefGoogle Scholar
  125. 125.
    Stenvinkel P (1998) Leptin — a new hormone of definite interest for the nephrologist. Nephrol Dial Transplant 13: 1099–1101PubMedCrossRefGoogle Scholar
  126. 126.
    Stivelman JC (2000) Benefits of anaemia treatment on cognitive function. Nephrol Dial Transplant 15: 29–35PubMedCrossRefGoogle Scholar
  127. 127.
    Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 11: 971–975Google Scholar
  128. 128.
    Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J, Clarkson BD (1990) Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncrossresistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8: 1173–1186PubMedGoogle Scholar
  129. 129.
    Stüben G, Thews O, Pöttgen C, Knühmann K, Vaupel P, Stuschke M (2001) Recombinant human erythropoietin increases the radiosensitivity of xeno-grafted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 127: 346–350PubMedCrossRefGoogle Scholar
  130. 130.
    Teicher BA, Holden SA, al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50: 3339–3344PubMedGoogle Scholar
  131. 131.
    Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13: 139–168PubMedCrossRefGoogle Scholar
  132. 132.
    Teicher BA (1995) Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am 9: 475–506PubMedGoogle Scholar
  133. 133.
    Temple RM, Deary IJ, Winney RJ (1995) Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis. Nephrol Dial Transplant 10: 1733–1738PubMedGoogle Scholar
  134. 134.
    Thomas G (2001) The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 28 (Suppl 8): 60–65PubMedCrossRefGoogle Scholar
  135. 135.
    Tomida A, Tsuruo T (1999) Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 14: 169–177PubMedGoogle Scholar
  136. 136.
    Tsakiris D (2000) Morbiditiy and mortality reduction associated with the use of erythropoietin. Nephron 85 (Suppl 1): 2–8PubMedCrossRefGoogle Scholar
  137. 137.
    Varat MA, Adolph RJ, Fowler NO (1972) Cardiovascular effects of anemia. Am Heart J 83: 415–426PubMedCrossRefGoogle Scholar
  138. 138.
    Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (Suppl 2): 4–12PubMedGoogle Scholar
  139. 139.
    Wagner W, Hermann R, Hartlapp J, Esser E, Christoph B, Müller MK, Krech R, Koch O (2000) Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther Onkol 176: 73–80PubMedCrossRefGoogle Scholar
  140. 140.
    Warde P, O’Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J, Cummings BJ (1998) T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 41: 347–353PubMedCrossRefGoogle Scholar
  141. 141.
    Wigren T, Oksanen H, Kellokumpu-Lehtinen P (1997) A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol 123: 259–266PubMedGoogle Scholar
  142. 142.
    Williams WJ (1988) Examination of the blood. Hematology. McGraw-Hill Book, New York, pp 9–21Google Scholar
  143. 143.
    Yasunaga Y, Shin M, Miki T, Okuyama A, Aozasa K (1998) Prognostic factors of renal cell carcinoma: a multivariate analysis. J Surg Oncol 68: 11–18PubMedCrossRefGoogle Scholar
  144. 144.
    Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy ( FACT) measurement system. J Pain Symptom Manage 13: 63–74PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  1. 1.Department of Internal Medicine (Cancer Research), West German Cancer CenterUniversity of Essen Medical SchoolEssenGermany

Personalised recommendations